In an era of clinician shortages, those living in rural areas are at risk of not receiving needed care. Cardiologists are stepping up, but will it be enough?

Troponin has become a widely accepted cardiac biomarker for myocardial infarction patients admitted to emergency rooms. But just how reliable is troponin in determining if a heart attack is really a heart attack?

Improving the use of ICDs will involve discerning appropriate from inappropriate shocks, standardizing post-shock protocols and refining device programming.

Interest in Tc 99m PYP is growing as new therapies for cardiac amyloidosis show promise in late-stage clinical trials.

The FDA on Friday, July 13, joined more than 20 other countries in recalling medications containing valsartan, an active ingredient used to treat hypertension and heart failure. Some of the medications with valsartan have been contaminated with N-nitrosodimethylamine (NDMA), a probable human carcinogen.

KALAMAZOO, Michigan, USA, July 16, 2018 — Stryker Corporation announced today that the U.S. Food and Drug Administration has granted pre-market approval (PMA) for the Surpass Streamline Flow Diverter to treat unruptured large and giant wide neck intracranial aneurysms. The device is the second flow diverting stent to gain FDA approval in the U.S.

Women and black patients have higher coronary artery bypass grafting (CABG) mortality rates than men and white patients, according to new research published in the Journal of the American Heart Association.

Santa Fe cardiologist Roy Heilbron, MD, has been sentenced to more than four years in prison for medical fraud and obstruction of justice. He pleaded guilty to fraud last year.

The average blood pressure of American youths is declining, a new CDC report suggests, even as updated guidelines classify almost 800,000 more of them as hypertensive.

A new study, published July 11 in the Journal of the American Medical Association, suggests heart failure (HF) may be moderately hereditary.